115 related articles for article (PubMed ID: 8687451)
41. The "anti-pyrimidine effect" of hypoxia and brequinar sodium (NSC 368390) is of consequence for tumor cell growth.
Löffler M
Biochem Pharmacol; 1992 May; 43(10):2281-7. PubMed ID: 1599514
[TBL] [Abstract][Full Text] [Related]
42. Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects?
Ullrich A; Knecht W; Fries M; Löffler M
Eur J Biochem; 2001 Mar; 268(6):1861-8. PubMed ID: 11248707
[TBL] [Abstract][Full Text] [Related]
43. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
Jones SW; Penman SL; French NS; Park BK; Chadwick AE
Toxicol In Vitro; 2021 Apr; 72():105096. PubMed ID: 33460737
[TBL] [Abstract][Full Text] [Related]
44. Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression.
Neidhardt EA; Punreddy SR; McLean JE; Hedstrom L; Grossman TH
J Mol Microbiol Biotechnol; 1999 Aug; 1(1):183-8. PubMed ID: 10941801
[TBL] [Abstract][Full Text] [Related]
45. Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors.
DeFrees SA; Sawick DP; Cunningham B; Heinstein PF; Morré DJ; Cassady JM
Biochem Pharmacol; 1988 Oct; 37(20):3807-16. PubMed ID: 2847745
[TBL] [Abstract][Full Text] [Related]
46. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Kadir MFA; Othman S; Nellore K
Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
[TBL] [Abstract][Full Text] [Related]
47. The cytotoxicity of methyl protoneogracillin (NSC-698793) and gracillin (NSC-698787), two steroidal saponins from the rhizomes of Dioscorea collettii var. hypoglauca, against human cancer cells in vitro.
Hu K; Yao X
Phytother Res; 2003 Jun; 17(6):620-6. PubMed ID: 12820229
[TBL] [Abstract][Full Text] [Related]
48. Catalytic enzyme histochemistry and biochemical analysis of dihydroorotate dehydrogenase/oxidase and succinate dehydrogenase in mammalian tissues, cells and mitochondria.
Löffler M; Becker C; Wegerle E; Schuster G
Histochem Cell Biol; 1996 Feb; 105(2):119-28. PubMed ID: 8852433
[TBL] [Abstract][Full Text] [Related]
49. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
Bruneau JM; Yea CM; Spinella-Jaegle S; Fudali C; Woodward K; Robson PA; Sautès C; Westwood R; Kuo EA; Williamson RA; Ruuth E
Biochem J; 1998 Dec; 336 ( Pt 2)(Pt 2):299-303. PubMed ID: 9820804
[TBL] [Abstract][Full Text] [Related]
50. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS
Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734
[TBL] [Abstract][Full Text] [Related]
51. N-phenyl ureidobenzenesulfonates, a novel class of promising human dihydroorotate dehydrogenase inhibitors.
Bouzriba C; Larcher L; Gagné-Boulet M; Fortin S
Bioorg Med Chem; 2020 Nov; 28(22):115739. PubMed ID: 33007554
[TBL] [Abstract][Full Text] [Related]
52. Catalytic properties of dihydroorotate dehydrogenase from Saccharomyces cerevisiae: studies on pH, alternate substrates, and inhibitors.
Jordan DB; Bisaha JJ; Picollelli MA
Arch Biochem Biophys; 2000 Jun; 378(1):84-92. PubMed ID: 10871048
[TBL] [Abstract][Full Text] [Related]
53. Multicenter phase II study of brequinar sodium in patients with advanced lung cancer.
Maroun J; Ruckdeschel J; Natale R; Morgan R; Dallaire B; Sisk R; Gyves J
Cancer Chemother Pharmacol; 1993; 32(1):64-6. PubMed ID: 8384937
[TBL] [Abstract][Full Text] [Related]
54. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
55. The cytotoxicity of protoneodioscin (NSC-698789), a furostanol saponin from the rhizomes of Dioscorea collettii var. hypoglauca, against human cancer cells in vitro.
Hu K; Yao X
Phytomedicine; 2002 Sep; 9(6):560-5. PubMed ID: 12403167
[TBL] [Abstract][Full Text] [Related]
56. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
[TBL] [Abstract][Full Text] [Related]
58. Mechanism of flavin reduction in class 2 dihydroorotate dehydrogenases.
Fagan RL; Nelson MN; Pagano PM; Palfey BA
Biochemistry; 2006 Dec; 45(50):14926-32. PubMed ID: 17154530
[TBL] [Abstract][Full Text] [Related]
59. 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.
Bradshaw TD; Wrigley S; Shi DF; Schultz RJ; Paull KD; Stevens MF
Br J Cancer; 1998 Mar; 77(5):745-52. PubMed ID: 9514053
[TBL] [Abstract][Full Text] [Related]
60. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]